Swissmedic grants temporary authorization for the Nuvaxovid COVID-19 vaccine from Novavax

22. April 2022 – As another alternative to the mRNA vaccines from Pfizer and Moderna and the vector vaccine from Johnson & Johnson, Swissmedic has authorized the protein-based vaccine Nuvaxovid (manufacturer: American pharmaceutical company Novavax) in Switzerland. It contains a component of the surface of the Sars-CoV-2 virus and an adjuvant that enhances the immune response. According to the documentation assessed by the Swiss Agency for Therapeutic Products, the level of protection afforded seven days after the second dose of the vaccine is approximately 90 percent. This is the fourth COVID-19 vaccine to be authorized in Switzerland.

For more information, see here and here.